Risk of Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies

Concurrent infections in hematological malignancies (HM) are major contributors to adverse clinical outcomes, including prolonged hospitalization and reduced life expectancy. Individuals diagnosed with HM are particularly susceptible to infectious pathogens due to immunosuppression, which can either...

Descripción completa

Detalles Bibliográficos
Autor principal: Andreescu, Mihaela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302360/
https://www.ncbi.nlm.nih.gov/pubmed/37374055
http://dx.doi.org/10.3390/life13061272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302360/
https://www.ncbi.nlm.nih.gov/pubmed/37374055
http://dx.doi.org/10.3390/life13061272

Ejemplares similares